ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act By Ogkologos - June 11, 2025 747 0 Facebook Twitter Google+ Pinterest WhatsApp Ensuring equitable access to cancer treatments remains central to EU health security efforts Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab April 16, 2024 4,000 Cancer Patients Affected by Diluted Chemotherapy Doses from Crooked Pharmacist September 17, 2020 Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours September 5, 2023 Spring Budget 2023: What does it mean for the mission to... March 15, 2023 Load more HOT NEWS Nomination Process for the 2026 ESMO Society Awards Now Open NHL Player Carey Price Surprises 11-Year-Old Boy Who Just Lost Mom... FDA Approves First Comprehensive Pan-Tumour Liquid Biopsy Test for Patients with... Panitumumab Added to Infusional Fluorouracil Plus Leucovorin May Be a Reasonable...
